EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amelioration of Fibrosis via S1P Inhibition Is Regulated by Inactivation of TGF-β and SPL Pathways in the Human Cornea

Sarah E Nicholas, Sandip K Basu, Nawajes Mandal iD, Dimitrios Karamichos iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sarah E Nicholas und 3 weiteren Autor:innen. Beteiligte Einrichtung: North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Hauptthemen laut MEDLINE: Sphingosine, Lysophospholipids, Fibrosis, Cornea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human corneal fibrosis can lead to opacity and ultimately partial or complete vision loss. Currently, corneal transplantation is the only treatment for severe corneal fibrosis and comes with the risk of rejection and donor shortages. Sphingolipids (SPLs) are known to modulate fibrosis in various tissues and organs, including the cornea. We previously reported that SPLs are tightly related to both, transforming growth factor beta (TGF-β) signaling and corneal fibrogenesis. The aim of this study was to investigate the effects of sphingosine-1-phosphate (S1P) and S1P inhibition on specific TGF-β and SPL family members in corneal fibrosis. Healthy human corneal fibroblasts (HCFs) were isolated and cultured in EMEM + FBS + VitC (construct medium) on 3D transwells for 4 weeks. The following treatments were prepared in a construct medium: 0.1 ng/mL TGF-β1 (β1), 1 μM sphingosine-1-phosphate (S1P), and 5 μM Sphingosine kinase inhibitor 2 (I2). Five groups were tested: (1) control (no treatment); rescue groups; (2) β1/S1P; (3) β1/I2; prevention groups; (4) S1P/β1; and (5) I2/β1. Each treatment was administered for 2 weeks with one treatment and switched to another for 2 weeks. Using Western blot analysis, the 3D constructs were examined for the expression of fibrotic markers, SPL, and TGF-β signaling pathway members. Scratch assays from 2D cultures were also utilized to evaluate cell migration We observed reduced fibrotic expression and inactivation of latent TGF-β binding proteins (LTBPs), TGF-β receptors, Suppressor of Mothers Against Decapentaplegic homologs (SMADs), and SPL signaling following treatment with I2 prevention and rescue compared to S1P prevention and rescue, respectively. Furthermore, we observed increased cell migration following stimulation with I2 prevention and rescue groups, with decreased cell migration following stimulation with S1P prevention and rescue groups after 12 h and 18 h post-scratch. We have demonstrated that I2 treatment reduced fibrosis and modulated the inactivation of LTBPs, TGF-β receptors, SPLs, and the canonical downstream SMAD pathway. Further investigations are warranted in order to fully uncover the potential of utilizing SphK I2 as a novel therapy for corneal fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SphingosineLysophospholipidsFibrosisCorneaSignal TransductionTransforming Growth Factor betaHumansFibroblastsCells, CulturedSphingolipidsPhosphotransferases (Alcohol Group Acceptor)Corneal Diseases

Stichwörter der Autor:innen

LTBPS1PSMADSphK I2TGF-βcorneal fibrosisfibrotic preventionfibrotic rescuesphingosine kinase inhibitor 2

Substanzen

sphingosine 1-phosphateSphingosineLysophospholipidsTransforming Growth Factor betaSphingolipidsPhosphotransferases (Alcohol Group Acceptor)

Autor:innen und Institutionen

  • North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
  • Department of Pharmaceutical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
  • Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
  • Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
  • Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

ORCID-Profile: Nawajes Mandal, Dimitrios Karamichos

Förderung

  • NEI NIH HHS
  • National Eye Institute

Zitieren

APA

Nicholas, S. E., Basu, S. K., Mandal, N., & Karamichos, D. (2024). Amelioration of Fibrosis via S1P Inhibition Is Regulated by Inactivation of TGF-β and SPL Pathways in the Human Cornea. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126560

Vancouver

Nicholas SE, Basu SK, Mandal N, Karamichos D. Amelioration of Fibrosis via S1P Inhibition Is Regulated by Inactivation of TGF-β and SPL Pathways in the Human Cornea. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126560

BibTeX
@article{Nicholas2024,
  author = {Nicholas, Sarah E and Basu, Sandip K and Mandal, Nawajes and Karamichos, Dimitrios},
  title = {Amelioration of Fibrosis via S1P Inhibition Is Regulated by Inactivation of TGF-β and SPL Pathways in the Human Cornea},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126560}
}
Kostenlos starten →